LDS/Medical Tests/Oncomine Dx (CDx) for Non–Small Cell Lung Cancer (NSCLC) Treatment Monitoring

Oncomine Dx (CDx) for Non–Small Cell Lung Cancer (NSCLC) Treatment Monitoring

The Oncomine Dx Target Test is an in vitro diagnostic, next-generation sequencing test designed to detect somatic alterations in DNA and RNA isolated from non-small cell lung cancer (NSCLC). This test mainly detects single-nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin fixed paraffin embedded (FFPE) tumor tissue samples. Target genes include: AKT1, ALK, BRAF, CDK4, DDR2, EGFR, ERBB2, ERBB3, FGFR2, FGFR3, HRAS, KIT, KRAS, MAP2K1 (aka MEK1), MAP2K2 (aka MEK2), MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, and ROS1. This test is an FDA-approved companion diagnostic indicated as an aid for selecting NSCLC patients for three targeted therapies:

  • Tafinlar® in combination with Mekinist® (dabrafenib/trametinib) in the presence of BRAF V600E mutation
  • Xalkori® (crizotinib) with ROS1 fusions; and
  • Iressa® (gefitinib) with EGFR L858R mutation or exon 19 deletions.
  • To help identify patients with EGFR Exon20 insertion mutation-positive in metastatic non-small cell lung cancer (mNSCLC) as candidates for EXKIVITY(mobocertinib) treatment
  • As an aid in selecting NSCLC patients for treatment with XALKORI® (crizotinib)
  • As an aid in selecting NSCLC patients for treatment with Tafinlar
  • Mekinist® (dabrafenib in combination with trametinib)
  • As an aid in selecting NSCLC patients for treatment with IRESSA® (gefitinib)
  • As an aid in selecting NSCLC patients for treatment with Gavreto® (pralcetinib)
  • Positive: BRAF V600E, associated therapy- Tafinlar+ Mekinist® (dabrafenib in combination with trametinib)
  • Positive: ROS1 fusion, associated therapy- XALKORI® (crizotinib)
  • Positive: RET fusion, associated therapy- Gavreto® (pralcetinib)
  • Positive: EGFR L858R– and Exon 19 deletion (associated therapy- IRESSA® (gefitinib)

No pathogenic variants (mutations) detected

Next generation sequencing (NGS).

Formalin fixed paraffin embedded (FFPE) tissue samples.

Stability

FFPE samples are stable at room temperature for longer. 

Lung biopsy/fine needle aspiration, liquid biopsy or ctDNA, fluorescent in situ hybridization.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login